Global Absence and Targeting of Protective Immune States in Severe COVID-19
| Autor: | Carolyn S. Calfee, Wandi S Zhu, Nicholas F. Kuhn, Aleksandra Leligdowicz, Mark R. Looney, Alexis J. Combes, Alyssa Ward, Divyashree Kushnoor, Michael R. Wilson, David Lee, Kenneth H. Hu, Arja Ray, William S. Chen, Carolyn M. Hendrickson, Lauren Rodriguez, David J. Erle, Kirsten N. Kangelaris, Colin R. Zamecnik, Nayvin W. Chew, Jessica Tsui, Gabriella C Reeder, Arjun A. Rao, Kamir J Hiam-Galvez, Yang Sun, Prescott G. Woodruff, Simon J. Cleary, Michael A. Matthay, Chun Jimmie Ye, Ran You, Gabriela K. Fragiadakis, Sidney A. Carrillo, Alan Shen, Priscila Muñoz-Sandoval, Tristan Courau, Charles Langelier, Vincent Chan, Rita P. Loudermilk, Mélia Magnen, Matthew F. Krummel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | bioRxiv Research Square article-version (status) pre article-version (number) 1 |
| Popis: | While SARS-CoV-2 infection has pleiotropic and systemic effects in some patients, many others experience milder symptoms. We sought a holistic understanding of the severe/mild distinction in COVID-19 pathology, and its origins. We performed a whole-blood preserving single-cell analysis protocol to integrate contributions from all major cell types including neutrophils, monocytes, platelets, lymphocytes and the contents of serum. Patients with mild COVID-19 disease display a coordinated pattern of interferon-stimulated gene (ISG) expression across every cell population and these cells are systemically absent in patients with severe disease. Severe COVID-19 patients also paradoxically produce very high anti-SARS-CoV-2 antibody titers and have lower viral load as compared to mild disease. Examination of the serum from severe patients demonstrates that they uniquely produce antibodies with multiple patterns of specificity against interferon-stimulated cells and that those antibodies functionally block the production of the mild disease-associated ISG-expressing cells. Overzealous and auto-directed antibody responses pit the immune system against itself in many COVID-19 patients and this defines targets for immunotherapies to allow immune systems to provide viral defense. One Sentence Summary: In severe COVID-19 patients, the immune system fails to generate cells that define mild disease; antibodies in their serum actively prevents the successful production of those cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|